Showing results (1-10 of 579) with videos related to
Sort By:
Pageof 58
Trends in Molecular Medicine|January 31, 2006
Keratinocytes regain momentum as instigators of cutaneous inflammationBrian J NickoloffCurrent Directions in Autoimmunity|May 8, 2008
Immunobiology of acute cytotoxic drug reactionsBrian J NickoloffPsychotherapy and Psychosomatics|September 14, 2017
Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical StudiesChristopher E M Griffiths, Maurizio Fava, Andrew H Miller, et al.The Journal of Dermatological Treatment|July 15, 2020
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1Christopher E M Griffiths, Kim A Papp, Michael Song, et al.The Journal of Clinical and Aesthetic Dermatology|July 24, 2015
Psoriasis: The Poster Child for Bench-to-bedside Translational MedicineLotus Mallbris, Brian J NickoloffJournal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trialAndrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.Journal of Drugs in Dermatology : JDD|August 21, 2018
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two YearsChristopher E M Griffiths, Kim A Papp, Alexa B Kimball, et al.Journal of the American Academy of Dermatology|April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trialKim A Papp, Joseph F Merola, Alice B Gottlieb, et al.The Journal of Clinical Investigation|June 17, 2004
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunitiesBrian J Nickoloff, Frank O NestleRecent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|June 25, 2002
Etiology and pathogenesis of Kaposi's sarcomaBrian J Nickoloff, Kimberly E ForemanPageof 58